爱优特®(呋喹替尼/fruquintinib)获纳入联合达伯舒®(信迪利单抗注射液)用于治疗既往系统性抗肿瘤治疗 后失败且不适合进行根治性手术治疗或根治性放疗的晚期错配修复完整(pMMR)子宫内膜癌患者。爱优 特®还获续约用于治疗既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或 不适合接受抗血管内皮生长因子(VEGF)治疗、抗表皮生长因子受体(EGFR)治疗(RAS野生型)的转移性 结直肠癌患者。 格隆汇12月8日丨和黄医药(00013.HK)宣布，经过与中国国家医疗保障局("国家医保局")的医保续约，爱 优特®(ELUNATE®)、沃瑞沙®(ORPATHYS®)和苏泰达®(SULANDA®)将继续获纳入自2026年1月1日起 生效的新版《国家基本医疗保险、工伤保险和生育保险药品目录》("国家医保药品目录")。此外，达唯 珂®(TAZVERIK®)获纳入首版国家商业健康保险创新药品目录(简称"商保创新药目录")。 沃瑞沙®(赛沃替尼/savolitinib)获纳入用于治疗携带间质-上皮转化因子(MET)外显子14跳变的局部晚期 或转移性非小细胞肺癌成人患者。 苏泰达®(凡替尼/suruf ...

Core Viewpoint - The announcement by the company indicates that its drug, Enze Shu (Suvorexant injection), has been officially included in the National Medical Insurance Catalog for 2025, effective from January 1, 2026, which is a significant milestone for the company and its product offerings [1] Group 1: Drug Approvals and Listings - Enze Shu has been approved for the treatment of adult patients with recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have received no more than one prior systemic therapy [1] - The drug was granted market approval in China on June 30, 2025, marking its entry into the market [1] - The company’s other drug, Endu (recombinant human vascular endothelial growth factor inhibitor injection), has successfully completed the renewal process for inclusion in the National Reimbursement Drug List (NRDL) [1] Group 2: Market Position and Significance - Enze Shu is a next-generation recombinant humanized monoclonal antibody targeting VEGF, which positions it as a novel treatment option in the oncology space [1] - Endu is recognized as China's first anti-angiogenesis targeted drug and the only endothelial inhibitor approved for sale globally, establishing it as a cornerstone treatment for advanced non-small cell lung cancer since its inclusion in the NRDL in 2017 [1]

备受创新药产业界关注的首版商保创新药目录清单终于"出炉"，共计纳入18家创新药企的19种新药。 第一财经进一步梳理发现，国产和进口药占比大致相当，6款新药在中国上市仅1年左右。从治疗领域来看，肿瘤药占比达七成，其中包含5款"天价抗癌 药"CAR-T产品。 此外，多款罕见病用药和阿尔茨海默病治疗用药也或因为纳入商保创新药目录，有望迎来更广阔的商保支付空间和"进院"的政策优待。 国产和进口药占比大致相当，6款新药在中国上市仅1年左右。 为何仅19种药品入选 12月7日，2025年国家医保药品目录及首版商保创新药目录在广州发布，19种药品纳入首版商保创新药目录。 | 药品 | 药企 | | --- | --- | | 1 伊匹木单抗注射液 | 百时美庭 | | | 宝 | | | 天津红 [ | | 2 甲苯磺酰胺注射液 | 达康医を | | | 技有限么 | | 3 氢溴酸他泽司他片 | 和记黄坑 | | 4 注射用芦比替定 | 南京绿叶 | | | ਯੁ | | 5 那西妥单抗注射液 | 赛生医を | | 6 盐酸沙丙蝶吟片 | 山东新町 | | | 载 7下 | | 8 达妥昔单抗β 注射液 | 百济神少 | ...

Core Insights - 康方生物's five approved drugs have been successfully included in the latest National Medical Insurance Drug List (2025) by the National Healthcare Security Administration of China, effective from January 1, 2026 [1][2][3] Group 1: Drug Approvals and Indications - 开坦尼 (卡度尼利, PD-1/CTLA-4) has renewed its existing indication for recurrent or metastatic cervical cancer and added new indications for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer, as well as first-line treatment for persistent, recurrent, or metastatic cervical cancer [1] - 依达方 (依沃西, PD-1/VEGF) has renewed its existing indication for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after progression on EGFR TKI treatment and added a new indication for first-line treatment of PD-L1 positive (TPS≥1%) locally advanced or metastatic NSCLC [1] - 安尼可 (派安普利, PD-1) is included for the treatment of second-line and above classical Hodgkin lymphoma, first-line locally advanced or metastatic squamous NSCLC, second-line or above nasopharyngeal carcinoma, and first-line nasopharyngeal carcinoma [2] - 伊喜宁 (伊努西, PCSK9) is included for the treatment of primary hypercholesterolemia and mixed hyperlipidemia, as well as heterozygous familial hypercholesterolemia [2] - 爱达罗 (依若奇, IL-12/IL-23) is included for the treatment of moderate to severe plaque psoriasis [3] Group 2: Company Commitment and Future Plans - The company is dedicated to providing more globally innovative and best-in-class treatment options, continuously improving patient accessibility and affordability [3] - The company aims to deepen its focus in various disease areas and promote more innovative drugs and new indications to be included in the National Medical Insurance Drug List, benefiting more patients [3]

新华社权威快报 2025年药品目录谈判协商结果12月7日在广州发布 114神药品 进入国家医保药品目录 19和药品 纳入首版商保创新药目录 2026年1月1日起实施 新华社国内部出品 记者12月7日从国家医保局获悉，2025年国家医保药品目录及首版商保创新药目录在广州发布。 2025年国家医保药品目录成功新增114种药品，有50种是一类创新药，总体成功率88%，较2024年的 76%明显提高。19种药品纳入首版商保创新药目录。 2025年国家医保药品目录纳入了一些弥补基本医保保障空白的药品，如三阴乳腺癌、胰腺癌、肺癌 等重大疾病用药；朗格汉斯细胞组织细胞增生症、螯合剂不耐受的地中海贫血症等罕见病用药；糖尿 病、高胆固醇血症、自身免疫性疾病等慢性病用药。 纳入首版商保创新药目录的19种药品中，既有CAR-T等肿瘤治疗药品，也有神经母细胞瘤、戈谢病 等罕见病治疗药品，还有阿尔茨海默病治疗药品等。 此次调整后，国家医保药品目录内药品总数增至3253种，其中西药1857种、中成药1396种，肿瘤、 慢性病、精神疾病、罕见病、儿童用药等重点领域的保障水平得到明显提升。 记者：彭韵佳、徐鹏航、徐弘毅 海报制作：彭韵佳 新 ...